Formulary Watch |

FDA Approves Therapy for Age-Related Blurry Vision

Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.

FDA Approves Novel Therapy for Chronic Myeloid Leukemia

Novartis’ Scemblix was approved for previously treated patients and for those who are resistant to TKI inhibitors.

Formulary Watch Drug Shortages Update — October 31, 2021

FDA Issues EUA for Pfizer COVID-19 Vaccine for Children

The dose is one-third of the dose given to people 12 years and older.

Concerns About Childhood COVID-19 Vaccines Persist, Despite FDA Committee OK

Generic of Decadron is Launched to Treat COVID-19

Dexamethasone is recommended by the NIH and the World Health Organization for treating COVID-19.

Segal: Specialty Drugs Driving Cost Trend

FDA Accepts Novartis’ Application for New Indication for Kymriah

Novatis is seeking approval for Kymriah in adult patients with advanced follicular lymphoma.

FDA Advisory Committee Recommends Pfizer Vaccine for Children

The phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in children 5 to 11 years of age.

FDA Clears Novel Pain Treatment

Boehringer Ingelheim Updates Safety Labeling of Cyltezo

Cigna Releases Formulary Changes for 2022

Study: Spending Increasing for Cancer Therapies Without Evidence of Overall Survival

FDA Approves Targeted Therapy for Macular Edema

Xipere is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.

AllianceRx: Number of Specialty Drugs Expected to Increase

Formulary Watch Drug Shortages Update — October 24, 2021

FDA Approves Novel Therapy for Macular Degeneration

Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.

Oncopeptides Withdraws Pepaxto from U.S. Market

Oncopeptides will close down its business units in the United States and Europe to focus exclusively on being a Sweden-based R&D company.

FDA Approves Dupixent for Children with Asthma

Developed by Regeneron Pharmaceuticals and Sanofi, Dupixent reduced severe asthma attacks and improved lung function in children 6 to 11 years.

Additional COVID-19 Vaccine Boosters Receive EUA; Positive Results for Pfizer Booster

Point32Health, Takeda Sign Risk Sharing Agreement for Alunbrig

If a patient does not remain on the drug for at least three months due to effectiveness or tolerability, a significant portion of the drug cost will be refunded to Point32Health.

Tecentriq Approved as First Adjuvant Immunotherapy for NSCLC

Prime Therapeutics Reviews Treatment Costs for Rare Blood Disease

FDA Approves Generic of Revlimid

Dr. Reddy’s received FDA approval for two strengths of lenalidomide for the treatment of patients with multiple myeloma.

Survey: Biosimilars are Gaining Momentum Among Payers

Merck Recalls One Lot of Cubicin

Glass was found in one vial of Cubicin, which treats patients with Staph infections of the skin and blood.

Express Scripts Adds Biosimilar Semglee to Preferred Formulary

Express Scripts will put the first interchangeable biosimilar insulin on its National Preferred Formulary and exclude Lantus, the reference product.

FDA Misses PDUFA Date for Bimekizumab

COVID-19 travel restrictions have hindered the FDA’s ability to inspect European manufacturing facilities for bimekizumab, which is under review for the treatment of patients with psoriasis.

FDA Approves ZIMHI to Treat Opioid Overdose

ZIMHI is the second product approved by the FDA to counteract opioid, and it is a high-dose naloxone expected to be launched in the first quarter of 2022.

Survey: Payers are Creating New Reimbursement Solutions for Gene Therapies